BR112012003907A2 - composições farmacêuticas para prevenção ou tratamento da osteoporose, a ser adminstrada uma vez por mês - Google Patents

composições farmacêuticas para prevenção ou tratamento da osteoporose, a ser adminstrada uma vez por mês

Info

Publication number
BR112012003907A2
BR112012003907A2 BR112012003907A BR112012003907A BR112012003907A2 BR 112012003907 A2 BR112012003907 A2 BR 112012003907A2 BR 112012003907 A BR112012003907 A BR 112012003907A BR 112012003907 A BR112012003907 A BR 112012003907A BR 112012003907 A2 BR112012003907 A2 BR 112012003907A2
Authority
BR
Brazil
Prior art keywords
month
administered once
osteoporosis
salt
pharmaceutical composition
Prior art date
Application number
BR112012003907A
Other languages
English (en)
Inventor
Byong-Sun Choi
Eun-Mi Kim
Geun-Hyeog Lee
Jae-Shin Kim
Jin-Ha Park
Jin-Sun Kim
O Mi-Jin
Original Assignee
Hanlim Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanlim Pharmaceutical Co Ltd filed Critical Hanlim Pharmaceutical Co Ltd
Publication of BR112012003907A2 publication Critical patent/BR112012003907A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

''composições farmacêuticas para prevenção ou tratamento da osteoporose, a ser administrada uma vez por mês'' a presente invenção proporciona uma composição farmacêutica para prevenir ou tratar osteoporose a ser administrada uma vez por mês, a composição farmacêutica compreendendo um derivado de bisfosfonato, tal como ácido risedrônico (ou seu sal) ou ácido ibandrônico (ou seu sal) e colecalciferal em uma dose alta. a presente invenção também fornece uma uma composição farmacêutica para prevenir ou tratar osteoporose a ser administrada uma vez por mês, compreendendo a composição farmacêutica: (a) colecalciferol em uma quantidade correspondente a 24.000 a 50.000 ui; (ii) um ou mais selecionados de acetato de tocoferil, butilhidroxitolueno e butilhydroxianisol como um primeiro agente estabilizador; e (iii) um aglutinante em etanol ou uma solução aquosa de etanol, (b) manitol como um segundo agente estabilizador e (c) ácido risedrônico ou seu sal ácido ibandrônico ou seu sal.
BR112012003907A 2009-09-18 2010-06-17 composições farmacêuticas para prevenção ou tratamento da osteoporose, a ser adminstrada uma vez por mês BR112012003907A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090088480A KR101102364B1 (ko) 2009-09-18 2009-09-18 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물
PCT/KR2010/003920 WO2011034274A2 (ko) 2009-09-18 2010-06-17 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물

Publications (1)

Publication Number Publication Date
BR112012003907A2 true BR112012003907A2 (pt) 2016-03-22

Family

ID=43759131

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012003907A BR112012003907A2 (pt) 2009-09-18 2010-06-17 composições farmacêuticas para prevenção ou tratamento da osteoporose, a ser adminstrada uma vez por mês

Country Status (8)

Country Link
EP (1) EP2478909B1 (pt)
KR (1) KR101102364B1 (pt)
CN (2) CN103191138A (pt)
BR (1) BR112012003907A2 (pt)
MA (1) MA33676B1 (pt)
MX (1) MX343184B (pt)
RU (1) RU2533230C2 (pt)
WO (1) WO2011034274A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101230178B1 (ko) * 2010-06-10 2013-02-06 주식회사 네비팜 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
ITMI20120393A1 (it) * 2012-03-14 2013-09-15 Tiberio Bruzzese Formulazioni acquose di bisfosfonati, vitamina d e alcol benzilico adatte all'uso intramuscolare o sottocutaneo
MX350569B (es) * 2012-12-03 2017-09-11 Landsteiner Scient S A De C V Composicion farmaceutica estable para el tratamiento de osteoporosis.
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
KR20160144663A (ko) 2015-06-09 2016-12-19 최숙 제제 및 이의 제조방법
IT201600123773A1 (it) * 2016-12-06 2018-06-06 Abiogen Pharma Spa Composizione per il trattamento dell’osteoartrosi
CN108420797B (zh) * 2018-05-09 2022-05-03 南京海融制药有限公司 维生素d类似物制剂及其制备方法
KR102158375B1 (ko) * 2018-10-25 2020-09-21 단국대학교 천안캠퍼스 산학협력단 비타민 d 에멀젼 및 비스포스포네이트를 포함하는 복합 액상 제형 및 이의 골다공증 예방 또는 치료 용도
KR102211287B1 (ko) * 2018-12-21 2021-02-03 (주)휴온스 비타민 d 또는 이의 유도체를 포함하는 안정성이 개선된 액상 제제

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2963718B2 (ja) * 1990-03-06 1999-10-18 グレラン製薬株式会社 ビタミンｄ▲下３▼類含有製剤
JP2845342B2 (ja) * 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンｄ▲下３▼誘導体含有固形製剤組成物
KR100317935B1 (ko) 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
US20030072802A1 (en) * 2001-10-11 2003-04-17 R.T. Alamo Ventures, Inc. Sustained release topiramate
US20050070504A1 (en) 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
JP2005531532A (ja) * 2002-04-05 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド アレンドロナートおよびビタミンｄ製剤を用いる骨吸収阻害法
GB0330009D0 (en) * 2003-12-24 2004-01-28 Ferrosan As Probiotic tablet formulations
KR20050110814A (ko) 2004-05-19 2005-11-24 머크 앤드 캄파니 인코포레이티드 골 흡수를 억제하기 위한 조성물 및 방법
WO2005117906A1 (en) 2004-05-19 2005-12-15 Merck & Co., Inc. Combination for inhibiting bone resorption comprising a bisphosponate (alendrona) and a vitamin d (cholecalciferol)
US20050261250A1 (en) 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
WO2008026907A1 (es) * 2006-08-29 2008-03-06 Espinosa Abdala Leopoldo De Je Composición farmacéutica que comprende ibandronato y vitamina d3 para el tratamiento de osteoporosis
KR100822133B1 (ko) 2006-11-06 2008-04-15 한미약품 주식회사 비타민 ｄ 또는 이의 유도체의 고체분산체 및비스포스포네이트를 포함하는, 골다공증 예방 또는 치료용복합제제
KR100844256B1 (ko) * 2007-03-23 2008-07-07 코오롱제약주식회사 리세드로네이트와 비타민 ｄ를 포함하는 대사성 골질환치료용 약제조성물 및 이의 제조방법
KR101230178B1 (ko) * 2010-06-10 2013-02-06 주식회사 네비팜 골다공증 예방 또는 치료용 조성물 및 이의 제조방법

Also Published As

Publication number Publication date
RU2533230C2 (ru) 2014-11-20
KR20110030852A (ko) 2011-03-24
MX343184B (es) 2016-10-26
CN102497867B (zh) 2015-04-29
MX2012002786A (es) 2012-06-25
CN102497867A (zh) 2012-06-13
EP2478909A4 (en) 2014-02-26
EP2478909A2 (en) 2012-07-25
CN103191138A (zh) 2013-07-10
WO2011034274A3 (ko) 2011-05-19
RU2012109614A (ru) 2013-10-27
KR101102364B1 (ko) 2012-01-03
MA33676B1 (fr) 2012-10-01
WO2011034274A2 (ko) 2011-03-24
EP2478909B1 (en) 2018-04-25

Similar Documents

Publication Publication Date Title
BR112012003907A2 (pt) composições farmacêuticas para prevenção ou tratamento da osteoporose, a ser adminstrada uma vez por mês
BR112012024349A2 (pt) métodos de tratamento de carcinoma hepatocelular
DE602005027727D1 (de) Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin
BR112012018384A2 (pt) composição farmacêutica sólida com intensificadores e métodos de preparação da mesma.
EP2588116A4 (en) FORMULATIONS OF AN INTRAVENOUS SOLUTION OF POSACONAZOLE STABILIZED BY SUBSTITUTED BETA CYCLODEXTRIN
EA201390409A1 (ru) Составы с низкой дозой панкрелипазы и кишечно-растворимым покрытием
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
NZ591810A (en) Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
MY166014A (en) Combination therapy methods for treating proliferative diseases
MX364637B (es) Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc.
WO2012075081A3 (en) High-strength testosterone undecanoate compositions
MX2013011086A (es) (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
WO2009120697A3 (en) Method and compositions for treatment of cancer
BR112012019374A2 (pt) composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo
WO2009111846A4 (en) Mitochondrially delivered anti-cancer compounds
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
MX2021010595A (es) Composicion farmaceutica, preparacion y usos de la misma.
BR112015029468A2 (pt) sistema de dosagem não alimentar oralmente administrável; composição oralmente administrável; método para suplementar a nutrição de ferro em um indivíduo humano com necessidade do mesmo; método para mitigar um ou mais efeitos adversos gastrointestinais de ferro não absorvido
BR112015014092A2 (pt) administração oral transmucosal de acetato de glatirâmer
MX2009014178A (es) Composicion de microparticulas biocompatibles de acido alginico para la liberacion controlada de principios activos por via intravenosa.
BR112012020377A2 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
EA023535B9 (ru) Композиция водного радиопротекторного фармацевтического раствора и способ предотвращения, снижения или исключения эффектов ионизирующей радиации
WO2009008461A1 (ja) 性ホルモン感受性細胞増殖を原因とする疾患に対する医薬組成物
RU2015145451A (ru) Препараты для местного применения, содержащие гиалуроновую кислоту, вербаскозид и глицерофосфоинозитол
RU2014141615A (ru) Новое противоопухолевое средство, включающее комбинацию трех агентов

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]